View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/CMS | RIN: 0938-AT59 | Publication ID: Fall 2018 |
Title: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P) | |
Abstract:
This proposed rule would set forth programmatic and operational changes to the Medicare Advantage (MA) and prescription drug benefit programs for contract year 2020. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Economically Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: Yes | Unfunded Mandates: No |
EO 13771 Designation: Deregulatory | |
CFR Citation: 42 CFR 417 42 CFR 422 42 CFR 423 | |
Legal Authority: 42 U.S.C. 1302 42 U.S.C. 1395hh |
Legal Deadline:
None |
||||||
Statement of Need: This rule is necessary to make revisions to the Medicare Advantage (MA) and Prescription Drug Benefit programs to implement applicable provisions of the Bipartisan Budget Act of 2018 and based on our continued experience in the administration of the programs. |
||||||
Summary of the Legal Basis: This rule addresses multiple sections of the Social Security Act. It also implements sections 50323, 50311, and 50354 of the Bipartisan Budget Act of 2018. |
||||||
Alternatives: This rule implements provisions that require public notice and comment and are necessary for the upcoming contract year. We will continue to explore additional alternatives as we develop the rule. |
||||||
Anticipated Costs and Benefits: Preliminary estimates of the anticipated costs and benefits of this proposed rule indicate savings and burden reduction for the government, MA organizations, prescription drug plan sponsors, and providers. We expect some savings will also be passed onto beneficiaries in the form of increased benefit offerings and reduced premiums or cost sharing. Numerical estimates are pending and as we move toward publication, estimates of costs and benefits will be included in the proposed rule. |
||||||
Risks: |
||||||
Timetable:
|
Regulatory Flexibility Analysis Required: Undetermined | Government Levels Affected: Federal |
Small Entities Affected: Businesses, Governmental Jurisdictions, Organizations | Federalism: No |
Included in the Regulatory Plan: Yes | |
RIN Data Printed in the FR: No | |
Agency Contact: Michael Dibella Director, Division of Policy, Analysis, and Planning Department of Health and Human Services Centers for Medicare & Medicaid Services Center for Medicare, MS: C4-22-18, 7500 Security Boulevard, Baltimore, MD 21244 Phone:410 786-4480 Email: michael.dibella@cms.hhs.gov |